Barrett Ablation denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for barrett ablation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits the Number of Barrett's Esophagus Ablation Sessions — and Why You Can Appeal

Humana's quantity-limits denial for Barrett's esophagus ablation means the plan has determined that the number of ablation sessions requested or performed exceeds what its medical policy permits within a defined period. This denial is particularly common because Barrett's ablation frequently requires multiple planned treatment sessions to achieve complete eradication of dysplastic or metaplastic tissue — a reality that is well recognized in the gastroenterology community. When a quantity-limits denial is applied to a clinically planned staged protocol, the denial often misapplies the policy's intent, and appeal success rates are strong when the clinical rationale for additional sessions is clearly documented.

## Your Federal Appeal Rights

ACA §2719 requires ACA-regulated plans to provide internal appeal and independent external review rights. ERISA §503 applies to employer plans. You have approximately four months from denial to request external review. Expedited review is available when standard timelines would jeopardize your health.

## The Appeal Process

1. Request the denial letter with the specific quantity-limit applied. Humana must cite the policy provision and state how many sessions it considers the maximum. 2. File a Level 1 internal appeal within Humana's deadline, with documentation explaining why the additional session is clinically necessary and distinct from a simple repetition of prior treatment. 3. Proceed to Level 2 and external review if the internal appeal is denied. External reviewers applying objective clinical standards frequently reverse quantity-limit denials for staged therapeutic protocols.

## Documentation to Gather

• Diagnosis confirmation: Endoscopy and pathology records establishing the Barrett's esophagus diagnosis and dysplasia status at the time of each session.
• Prior-treatment history: Procedural notes from each prior ablation session with dates, the extent of tissue treated, and post-treatment endoscopy and biopsy findings showing residual or recurrent disease.
• Clinical severity: Current endoscopy and biopsy results showing what tissue remains to be treated and why continued ablation is medically necessary.
• Prescriber medical-necessity letter: A letter from your gastroenterologist explaining the planned multi-session treatment protocol, what has been accomplished in prior sessions, what remains, and why the additional session is a necessary component of the protocol — not a discretionary repeat.

## Criteria-Mapping Strategy

Obtain Humana's medical policy and identify what it states about quantity limits for Barrett's ablation. Determine whether the policy provides for exceptions based on clinical documentation of residual disease or incomplete response. Then document — using post-treatment endoscopy and biopsy findings — that the additional session addresses tissue that was not treated in prior sessions. Reference professional society guidelines from organizations such as the American Society for Gastrointestinal Endoscopy to support the recognized practice of staged, multi-session ablation protocols for this condition.